000518.SZJiangsu Sihuan Bioengineering Co., Ltd
The schedule
- Wed4Nov
Q3 2026 Earnings Release, testing the sustainability of biotech revenue pipelines under a strained balance sheet, anchoring at $3.35.
- Thu10Dec
Expected late-year clinical R&D update and strategic review of assets, starting from a depressed $2.90 level.
- Wed3Feb
- Mon15Feb
A critical window to address the balance sheet from $3.50, assessing the high probability of a dilutive equity offering to extend operational runway.
- Wed28Apr
FY 2026 Earnings Release and initial 2027 financial guidance, evaluating the fundamentals from $2.70.
- Wed5May
- Wed4Aug
Past
- Fri28Aug
Actual outcome: Bear · $3.79 at outcome
The stock closed at $3.79, below the bull target of $4.40 and above the bear floor of $3.35, indicating a bearish outcome. The earnings release showed an EPS miss and weak guidance, which overshadowed any potential positive catalysts. Despite some strategic announcements, the overall sentiment was negative due to underperformance and lack of confidence in future growth prospects.
Jiangsu Sihuan Bioengineering will report H1 2026 results from a $3.80 base. The focus is on whether the massive 85.14% YoY revenue growth can offset the widening net income losses.